Charles River Laboratories International (CRL) Equity Average (2016 - 2025)
Historic Equity Average for Charles River Laboratories International (CRL) over the last 16 years, with Q3 2025 value amounting to $3.4 billion.
- Charles River Laboratories International's Equity Average fell 990.39% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 990.39%. This contributed to the annual value of $3.5 billion for FY2024, which is 738.03% up from last year.
- Latest data reveals that Charles River Laboratories International reported Equity Average of $3.4 billion as of Q3 2025, which was down 990.39% from $3.3 billion recorded in Q2 2025.
- Charles River Laboratories International's 5-year Equity Average high stood at $3.8 billion for Q3 2024, and its period low was $2.2 billion during Q1 2021.
- Moreover, its 5-year median value for Equity Average was $3.2 billion (2023), whereas its average is $3.0 billion.
- In the last 5 years, Charles River Laboratories International's Equity Average skyrocketed by 3220.98% in 2021 and then crashed by 1103.22% in 2025.
- Over the past 5 years, Charles River Laboratories International's Equity Average (Quarter) stood at $2.5 billion in 2021, then grew by 12.93% to $2.8 billion in 2022, then grew by 23.14% to $3.5 billion in 2023, then rose by 4.93% to $3.6 billion in 2024, then decreased by 6.67% to $3.4 billion in 2025.
- Its Equity Average stands at $3.4 billion for Q3 2025, versus $3.3 billion for Q2 2025 and $3.3 billion for Q1 2025.